Hemophilia the Challenge for GeneTherapy
|
|
- Warren Crawford
- 7 years ago
- Views:
Transcription
1 Hemophilia the Challenge for GeneTherapy
2 Hemophilia The Challenge for Gene Therapy MEMBER OF THE STEERING COMMITTEE FOR THE UNIQURE AMT-060 TRIAL: > Dr. Wolfgang Miesbach Hemophilia Center Clinic of the Johann Wolfgang Goethe University Frankfurt, Germany 2
3 Frankfurt Hemophilia Center Background > One of the largest hemophilia treatment centers in Germany > Treatment of patients with hemophilia, von Willebrand disease and other defects since 1970 s > Treatment of patients with thrombophilia or patients with ITP or TTP > Comprehensive care center (24 h care) > Extensive experience with surgical procedures in hemophilia patients 3
4 Hemophilia A and B FEATURES HEMOPHILIA A HEMOPHILIA B PREVALENCE 1 : 5,000 males 1: 30,000 males COMMON CLINICAL SYMPTOMS Haemarthroses, muscle haematoma Haemarthroses, muscle haematoma BLEEDING FREQUENCY/YEAR (?) FVIII/FIX HALF-LIFE (H) CLONING FACTOR GENE MOLECULAR MASS PRIMARY STRUCTURE 265 kda 2332 amino acids 68 kda 265 amino acids MOST FREQUENT GENE DEFECT Intron 22 inversion Missense mutation INHIBITOR INCIDENCE (%)
5 Severe Hemophilia Spontaneous Bleeds, Joint Damage, Compliance MAIN MANIFESTATIONS > Joint bleeds > Chronic arthropathy > Disability SIGNIFICANT MEDICAL NEED > Frequent infusions of FIX / FVIII > Infusions are painful, require venous access > Prophylaxis is available only in countries that can afford it > Compliance > In-spite of current best standard of care patients still have bleeds 5
6 Current Treatment Approach COAGULATION FACTOR LEVELS SEVERITY OF DISEASE BLEEDING SYMPTOMS FVIII/IX < 1 % Severe Spontaneous FVIII/IX < 5 % Moderate Spontaneous and after trauma FVIII/IX > 5 % Mild After trauma or surgery CURRENT REPLACEMENT REGIMEN RISK OF BLEEDING INCREASES AT < 1% Collins,
7 Non-adherence in Hemophilia Zappa S et al. Haemophilia 2012 May; 18(3):e
8 Frequency of Discontinuation & Restarting of Prophylaxis In Adults with Severe Hemophilia COUNTRY PATIENTS DISCONTINUING PROPHYLAXIS (%) PATIENTS RESTARTING PROPHYLAXIS (%) USA 27/76 (36) 9/23 (39) EUROPE 92/218 (42) 26/92 (28) THE NETHERLANDS 18/58 (31) 0 DENMARK 10/22 (42) n.a. SWEDEN 3/42 (7) n.a. 8
9 Decrease the Burden of Treatment > Dosing interval > Route of administration > Immunogenicity > Safety profile > Long-acting therapies > Subcutaneous, intravenous etc. > Inhibitor development > Portability, devices, cost > Optimize individual treatment 9
10 Hemophilia Ideal Target for Gene Therapy > Molecular level well understood > Patients and treaters can be readily identified in specialist centers > Animal model exists > Single gene carried by various vectors > Correction of deficiency > 2% offers prospects of reducing bleeding tendency > Factor level in blood can be monitored easily 10
11 Factor IX Factor IX Hemophilia Gene Versus Replacement Therapy REPLACEMENT THERAPY 5% GENE THERAPY No spontaneous intermittent bleedings 5% 11
12 AAV8/FIX Single Intervention Reduces Need for Prophylactic Treatment (1) SUSTAINED, DOSE DEPENDENT EFFECT OVER > 4 YEARS AFTER A SINGLE INTERVENTION: > 4/6 high dose patients did not require further FIX treatment; 4/7 on prophylaxis could stop prophylaxis % Expression of normal Low-dose Mid-dose High-dose Presented in New England Journal of Medicine 12/2011 Oral Presentation Patient Patient 10 Disease Severity Mild Moderate Severe (1) Third party trial conducted by St. Jude s Children Research Hospital and UC London 12
13 AAV8/FIX Long-term Follow-up KEY POINTS: > 92% reduction of factor IX concentrate units used > Median annual bleeding episodes dropped from 15.5 to 1.5 (90%) Nathwani AC NEJM 2014; 371:
14 Inhibitor Formation in Hemophilia B > Inhibitors occur in 2-5% of patients with severe Hemophilia B on prophylactic therapy > Hepatic adeno associated viral (AAV) gene transfer in non-clinical studies may induce FIX specific immune tolerance (Cao et al, 2007; Dobrzynski et al, 2006; Mingozzi et al, 2003) > Clinical trials with liver directed AAV gene therapy support that FIX specific immune tolerance can be achieved > Whether pre-existing inhibitor can be reversed with AAV gene therapy remains to be determined 14
15 Clinical Trial with AAV5-FIX 15
16 Target Product Profile AAV5-FIX for the Treatment of Hemophilia B TARGET INDICATION: > Prevention of bleeding episodes (and to reduce the need for Factor IX replacement therapy) in patients with hemophilia B, plasma FIX activity <2% and with a history of frequent bleeding episodes requiring treatment with exogenous FIX or continuous FIX prophylaxis TARGET EXPRESSION LEVEL: <5% > Supported by non-clinical data: > NHP data support starting dose expression level close to 5% > Linear dose-response in NHP supports doubling potential of circulating FIX TARGET CLINICAL BENEFIT: 90% REDUCTION IN CONSUMPTION AND BLEEDING RATE > Supported by long-term follow-up data from Nathwani published in
17 Target Product Profile AAV5-FIX for the Treatment of Hemophilia B TARGET SAFETY PROFILE > Absence of organ toxicity and no need for immune suppression rescue treatment > Supported by AAV5 safety data obtained at similar dose levels in AIP patients > Immune tolerance of endogenous expressed FIX protein without inhibitor response against FIX > Supported by non-clinical and clinical data suggesting immune tolerance can be achieved with gene therapy > Favorable long-term safety profile > Supported by long-term follow-up with UCL FIX gene cassette by Nathwani > Risk of carcinogenicity negligible > Established for AAV with Glybera 17
18 Objectives 18
19 AAV5/FIX Phase I/II Dose Escalation Study Protocol Based on Cross Referencing POPULATION AAV8 mammalian AAV5 insect cell > 10 patients (severe bleeding phenotype) > Severe (< 1% FIX) on prophylactic therapy > Moderate ( 2% FIX) on-demand therapy Dose (gc/kg) High ( ) Mid ( ) Low ( ) ST Jude ST Jude ST Jude uniqure uniqure CROSS REFERENCING >St. Jude FIX safety data >Porphyria AAV5 safety data OBJECTIVES > Assess safety/tolerability > Define FIX expression level KEY EFFICACY ASSESSMENTS > Factor IX activity > FIX product consumption > Annual bleeding rate > Health related quality of life TIMELINES > Study begin Q1/15 > Study results Q4/15, interim Q2 / Q3 19
20 Other Relevant Design Details Intra-cohort Staggering 20
21 Inter-cohort Staggering Allows for Fast Trial Execution 21
22 Development Timelines Hemophilia B PRELIMINARY RESULTS Phase 1/2 INITIATE Phase 3 MID /17 1Q2015 MID 2016 START DOSING Phase 1/2 CLINICAL TRIAL REPORT Phase 1/2 22
23 Future Competitive Environment Product Pipeline Preclinical FIX-CTP; OPKO Health Phase 1 Other rfix Phase 2 ALN-AT3SC; Alnylam CB 2679d, Catalyst, ISU Abxis IXinity; Emergent Phase 3 Concizumab; Novo Nordisk N9-GP; Novo Nordisk CSL 654; CSL Pre-reg Gene therapy BAX 335; Baxter AMT 060; uniqure AAV8-hFIX19; Spark AAV10FIX; Dimension FIX gene editing; Shire BAX 817; Baxter LR769; revo, LFB Bypassing agents PF , Catalyst, Pfizer CSL 689 CSL 23
24 Global Perspectives of Gene Therapy Level of Prophylactic Treatment Varies with Country Economy and Health Care System % HAEMOPHILIA INDIVIDUALS ON PROPHYLAXIS < 18 YEARS % HAEMOPHILIA INDIVIDUALS ON PROPHYLAXIS > 18 YEARS 100 Germany >95% Germany 50% US 40% US 15% Countries Countries Source: WFH presentation by Mark Brooker, Prague, October
25 Summary of uniqure s Hemophilia B program All Elements in Place to Advance Rapidly into Pivotal > Full freedom to operate > 2 year AAV5 safety data from Porphyria trial > 4.5 year FIX cassette safety and efficacy data from St Jude trial > Industrial grade/scale manufacturing GENE CASSETTE FIX Cassette excl. license from St. Jude VECTOR AAV5 excl. license from NIH MANUFACTURING Safe, robust, scalable, proprietary 25
26 Summary Gene Therapy for Hemophilia > AAV based liver directed gene therapy can secure long term expression of FIX at therapeutically relevant levels (NEJM 2011) > > 90% Reduction in bleeding risk and consumption can be achieved (NEJM 2014) > Hemophilia patients are increasingly aware of the potential life changing benefits of gene therapy 26
27 Harald Petry, Ph.D.
28 Hemophilia A > Hemophilia A is a genetic, recessive disorder caused by production of dysfunctional or insufficient amount of factor VIII (FVIII) protein, a key protein involved in the blood coagulation cascade > Patients suffer from spontaneous bleeding in the large joints and soft tissue and are at risk for intracranial hemorrhage. Recurrent episodes of joint bleeding can lead to crippling arthropathy, particularly in severely affected patients > The majority of hemophilia cases are inherited X-linked recessive trait and therefore most frequently affects males. However cases due to spontaneous mutations also arise (up to 30%) > Hemophilia comprises the majority of hemophilia patients (80%), with incidence of ~1:10,000 to 1:50,000 males affecting 400,000 people worldwide 28
29 Packaging of FVIII Gene and Cellular Processing How Packaging of a Too-large FVIII Gene was Expected to Work HLP-coFVIII-N6 5.7 kb paav-hlp-cofviii-n6 HLP A1 A2 B / N6 A3 C1 C2 spa OVERSIZED raav Annealing of plus and minus genomes Transcription of the transgene protein expression Reassembly of the intact gene cassette during concatemer formation 29
30 AAV2/5-FVIII 4 e 13 AAV5-FVIII 1,2 e 14 pvd S/X Packaging of FVIII Gene and Cellular Processing How packaging of a Too-large FVIII Gene Actually Worked µg AAV DNA PACKAGED DNA concatemers concatemers HH HT EXPECTED CONCATAMERIC STRUCTURES 5 + _ raav vector 5 kb dsdna-concatamers M full length mrna Active protein 30
31 Achievements in 2014, Plans for 2015 On the Way to Phase I > A partially deleted B-domain FVIII variant has been shown to increase secretion of FVIII as compared to wild type or to FVIII with complete B-domain deletion > A raav5-based FVIII including this partial deletion has been generated in house and Proof of Concept has been demonstrated (i.e. production of active FVIII protein in vitro and in vivo) > Plans for 2015 > Screening of five proprietary FVIII constructs ongoing, first mouse results expected in December 2014 > NHP studies with own FVIII: pilot experiment planned to start in January in parallel generation of an antibody to discriminate between human and monkey FVIII > Generation of smaller expression cassettes to increase quality of the product. HEMOPHILIA A 31
32 04 Gene Therapy for Acquired Diseases: Congestive Heart Failure Patrick Most, M.D. 32
Delivering gene therapy to patients
Delivering gene therapy to patients FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements
More informationDelivering gene therapy to patients
Delivering gene therapy to patients FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements
More informationIrish Haemophilia Society. Introduction to Haemophilia. Brian O Mahony November 2009
Irish Haemophilia Society Introduction to Haemophilia Brian O Mahony November 2009 1 Content Introduction to Haemophilia Introduction to Von Willebrand's Disease Inheritance Bleeding patterns Introduction
More informationPhase 1 Study of ALN-AT3 An Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders.
Phase 1 Study of ALN-AT3 An Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders January 12, 2015 1 Agenda Welcome Cynthia Clayton Vice President, Investor Relations
More informationHAEMOPHILIA & UMBILICAL CORD BLOOD TRANSPLANT
HAEMOPHILIA & UMBILICAL CORD BLOOD TRANSPLANT Haemostatic System in Body Blood vessels Platelets Plasma coagulation system Proteolytic or Fibrinolytic system How Bleeding Stops Vasoconstriction Platelet
More informationGene Therapy- Past, Present and Future. Mark A. Kay MD, PhD Dennis Farrey Family Professor Departments of Pediatrics and Genetics Stanford University
Gene Therapy- Past, Present and Future Mark A. Kay MD, PhD Dennis Farrey Family Professor Departments of Pediatrics and Genetics Stanford University Definition of gene therapy Gene therapy is the introduction
More informationSUBMISSION ON THE FUNDING OF EXTENDED HALF LIFE FACTOR VIII CONCENTRATES
SUBMISSION ON THE FUNDING OF EXTENDED HALF LIFE FACTOR VIII CONCENTRATES WHO WE ARE In 1953, a small group of hemophiliacs, their families and physicians in Montreal founded the Canadian Hemophilia Society
More informationHemophilia Care. Will there always be new people in the world with hemophilia? Will hemophilia be treated more effectively and safely in the future?
Future of This chapter provides answers to these questions: Will there always be new people in the world with hemophilia? Will hemophilia be treated more effectively and safely in the future? Will the
More informationFREQUENTLY ASKED QUESTIONS (FAQ)
FREQUENTLY ASKED QUESTIONS (FAQ) Questions What is the ABDR? How does the National Blood Authority (NBA) know that I ve ordered clotting factor product? Which bleeding disorders are within the scope of
More informationnovo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Protein Technologies Diabetes Protein Delivery Devices
novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Juan Jenny Li works as a chemistry professional at Novo Nordisk s research centre in Beijing Diabetes Protein Technologies
More informationuniqure Announces Results for Fourth Quarter and Financial Year 2015
FOR IMMEDIATE RELEASE uniqure Announces Results for Fourth Quarter and Financial Year 2015 Amsterdam, the Netherlands, April 4, 2016 uniqure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced
More informationAlpha-1 Antitrypsin Deficiency A future NBS candidate?
Alpha-1 Antitrypsin Deficiency A future NBS candidate? Robert A. Sandhaus, MD, PhD Alpha-1 Antitrypsin Deficiency Condition: Alpha-1 antitrypsin deficiency, alpha-1 proteinase inhibitor deficiency, Alpha-1,
More informationATHN Assets for the Community: ATHNdataset Michael Recht, MD PhD 10/30/2014 1
ATHN Assets for the Community: ATHNdataset Michael Recht, MD PhD 10/30/2014 1 Sept. 2010 Dec. 2011 Mar. 2011 Jun. 2011 Sept. 2011 Dec. 2011 Mar. 2012 Jun. 2012 Sept. 2012 Dec. 2012 Mar. 2013 Jun. 2013
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationAddressing the Needs of Members with Hemophilia in Medicaid Managed Care: Issues and Implications for Health Plans
Addressing the Needs of Members with Hemophilia in Medicaid Managed Care: Issues and Implications for Health Plans Clinical Brief Medicaid Health Plans of America Center for Best Practices July 22, 2013
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationSummary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)
EMA/662624/2015 Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) This is a summary of the risk management plan (RMP) for Orkambi, which details the measures to be taken
More information2006 Provider Coding/Billing Information. www.novoseven-us.com
2006 Provider Coding/Billing Information 2 3 Contents About NovoSeven...2 Coverage...4 Coding...4 Reimbursement...8 Establishing Medical Necessity and Appealing Denied Claims...10 Claims Materials...12
More informationSOCIAL WORKERS IN HEMOPHILIA CARE STANDARDS OF PRACTICE May, 2009
SOCIAL WORKERS IN HEMOPHILIA CARE STANDARDS OF PRACTICE May, 2009 These standards are based on an original document prepared by Leonarda Szeweczyk, MSW CSW, Linda Prentice, MSW CSW Alison Oxalade, MSW,
More information9/16/2014. Advances in the Field of Bleeding Disorders Janus Series
Advances in the Field of Bleeding Disorders Janus Series Elizabeth Varga, MS, LGC Nationwide Children s Hospital Division of Hematology/Oncology/BMT Clinical Assistant Professor of Pediatrics The Ohio
More informationRational for secondary prophylaxis in VWD
Rational for secondary prophylaxis in VWD Susan Halimeh Medical Thrombosis and Haemophilia treatment Center, Duisburg, Germany Dr. med. Susan Halimeh When is prophylaxis in patients with VWD recommended?
More informationBecker Muscular Dystrophy
Muscular Dystrophy A Case Study of Positional Cloning Described by Benjamin Duchenne (1868) X-linked recessive disease causing severe muscular degeneration. 100 % penetrance X d Y affected male Frequency
More informationINTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
More informationTeriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).
Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The
More informationSession 6 Clinical Trial Assessment Phase I Clinical Trial
L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationCareers in Haematology
Careers in Haematology A Guide for Medical Students and Junior Doctors Haematology is the medical speciality concerned with blood disorders. Your non-medical friends however will always think that you
More informationFACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
More informationDie Zulassung von Ultra Orphans und die Rolle des COMP und CAT 14. DGRA Jahreskongress 30.-31.5.2012, Bonn
Die Zulassung von Ultra Orphans und die Rolle des COMP und CAT 14. DGRA Jahreskongress 30.-31.5.2012, Bonn Dr. med. Christian K Schneider Committee for Advanced Therapies (CAT), EMA, London CHMP Biosimilar
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER
European Medicines Agency London 23 April 2009 EMEA/CHMP/BMWP/102046/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR MEDICINAL
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
More informationINTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
More informationProspects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS
Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates
More informationCHAPTER 15 THE CHROMOSOMAL BASIS OF INHERITANCE. Section B: Sex Chromosomes
CHAPTER 15 THE CHROMOSOMAL BASIS OF INHERITANCE Section B: Sex Chromosomes 1. The chromosomal basis of sex varies with the organism 2. Sex-linked genes have unique patterns of inheritance 1. The chromosomal
More informationTreatment of Hemophilia A and B Marianne McDaniel, RN FACTOR REPLACEMENT CONCENTRATES AND VIRAL INACTIVATION
Treatment of Hemophilia A and B Marianne McDaniel, RN INTRODUCTION Treatment for patients with hemophilia and other bleeding disorders has evolved over the past several decades. Replacement of the specific
More informationPOST- ASH MEETING. Dr. Anna Vantilborgh Hematologie - UZ Gent. 6 januari 2012. 2010 Universitair Ziekenhuis Gent
POST- ASH MEETING Dr. Anna Vantilborgh Hematologie - UZ Gent 6 januari 2012 PLATELETS AND COAGULATION I. Thrombosis IA. New anti-aggregant drugs IB. New anticoagulant drugs II. Hemostasis Gene therapy
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
More informationNewsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:
Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report
More informationLABORATORY DIAGNOSIS OF BLEEDING DISORDERS
LABORATORY DIAGNOSIS OF BLEEDING DISORDERS Secondary Hemostasis CIRCULATORY SYSTEM Low volume, high pressure system Efficient for nutrient delivery to tissues Prone to leakage 2º 2 to endothelial surface
More informationLecture 6: Single nucleotide polymorphisms (SNPs) and Restriction Fragment Length Polymorphisms (RFLPs)
Lecture 6: Single nucleotide polymorphisms (SNPs) and Restriction Fragment Length Polymorphisms (RFLPs) Single nucleotide polymorphisms or SNPs (pronounced "snips") are DNA sequence variations that occur
More informationFSH Society s 2014 Biennial FSHD Connect Meeting: Natural History Studies
FSH Society s 2014 Biennial FSHD Connect Meeting: Natural History Studies Raymond A. Huml, MS, DVM, RAC Executive Director, Head, Global Biosimilars Business Development and Strategic Planning, Quintiles
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationAAV specific issues pertaining to vector shedding in gene therapy clinical trials. Samuel Wadsworth Genzyme Corporation
AAV specific issues pertaining to vector shedding in gene therapy clinical trials Samuel Wadsworth Genzyme Corporation Workshop objectives Assess the impact of vector design on shedding (studies) Review
More informationMuscular Dystrophy: Stem Cell Therapy
by Caitlin Pederson Abstract: Genetic disorders affect many people, and muscular dystrophy is a disorder that can greatly decrease the quality of life. Finding treatment to stop or prevent the loss of
More informationSummary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs
Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer
More informationTransgenic technology in the production of therapeutic proteins
Transgenic technology in the production of therapeutic proteins Transgenic technology represents a new generation of biopharmaceutical production system to meet the medical needs of the new millennium.
More informationICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
More informationSummary and general discussion
Chapter 7 Summary and general discussion Summary and general discussion In this thesis, treatment of vitamin K antagonist-associated bleed with prothrombin complex concentrate was addressed. In this we
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationLow Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small
More informationProof-of-Concept Studies and the End of Phase IIa Meeting with the FDA
Medpace Discovery Series presents Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA DR. JIM WEI: Today my topic is going to be Proof-of-Concept Studies and FDA End of Phase 2a Meetings
More informationALPHA (TNFa) IN OBESITY
THE ROLE OF TUMOUR NECROSIS FACTOR ALPHA (TNFa) IN OBESITY Alison Mary Morris, B.Sc (Hons) A thesis submitted to Adelaide University for the degree of Doctor of Philosophy Department of Physiology Adelaide
More informationBasic Overview of Preclinical Toxicology Animal Models
Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background
More informationZOVIRAX Cold Sore Cream
Data Sheet ZOVIRAX Cold Sore Cream Aciclovir 5% w/w Presentation Topical cream Indications ZOVIRAX Cold Sore Cream is indicated for the treatment of Herpes simplex virus infections of the lips and face
More informationClinical trials in haemophilia
Clinical trials in haemophilia Dr. Paul Giangrande Oxford Haemophilia and Thrombosis Centre & Nuffield Department of Clinical Medicine University of Oxford paul.giangrande@ndm.ox.ac.uk Why do clinical
More informationSummary of the risk management plan (RMP) for Cerdelga (eliglustat)
EMA/743948/2014 Summary of the risk management plan (RMP) for Cerdelga (eliglustat) This is a summary of the risk management plan (RMP) for Cerdelga, which details the measures to be taken in order to
More informationBioBoot Camp Genetics
BioBoot Camp Genetics BIO.B.1.2.1 Describe how the process of DNA replication results in the transmission and/or conservation of genetic information DNA Replication is the process of DNA being copied before
More informationBIOTECHNOLOGY OPERATIONS
BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationGene mutation and molecular medicine Chapter 15
Gene mutation and molecular medicine Chapter 15 Lecture Objectives What Are Mutations? How Are DNA Molecules and Mutations Analyzed? How Do Defective Proteins Lead to Diseases? What DNA Changes Lead to
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationUniversity of Utah CME Statement
University of Utah CME Statement The University of Utah School of Medicine adheres to ACCME Standards regarding industry support of continuing medical education. Speakers are also expected to openly disclose
More informationNew Approaches to a Major Public-Health Problem Infectious Diseases. Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head
New Approaches to a Major Public-Health Problem Infectious Diseases Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head Overview The Burden Of Infectious Disease Is Large And May
More informationProvided by the American Venous Forum: veinforum.org
CHAPTER 3 CLOTTING DISORDERS Original authors: Edith A. Nutescu, Jessica B. Michaud, Joseph A. Caprini, Louis W. Biegler, and Robert R. McCormick Abstracted by Kellie R. Brown Introduction The normal balance
More information4.1 Objectives of Clinical Trial Assessment
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
More informationGenetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association
6 Genetic testing The difference diagnostics can make The British In Vitro Diagnostics Association Genetic INTRODUCTION testing The Department of Health published Our Inheritance, Our Future - Realising
More informationNORD Guides for Physicians #1. Physician s Guide to. Tyrosinemia. Type 1
NORD Guides for Physicians #1 The National Organization for Rare Disorders Physician s Guide to Tyrosinemia Type 1 The original version of this booklet was made possible by donations in honor of Danielle
More informationNational Patient Safety Goals Effective January 1, 2015
National Patient Safety Goals Effective January 1, 2015 Goal 1 Improve the accuracy of resident identification. NPSG.01.01.01 Long Term are ccreditation Program Medicare/Medicaid ertification-based Option
More information1 Mutation and Genetic Change
CHAPTER 14 1 Mutation and Genetic Change SECTION Genes in Action KEY IDEAS As you read this section, keep these questions in mind: What is the origin of genetic differences among organisms? What kinds
More informationMUTATION, DNA REPAIR AND CANCER
MUTATION, DNA REPAIR AND CANCER 1 Mutation A heritable change in the genetic material Essential to the continuity of life Source of variation for natural selection New mutations are more likely to be harmful
More informationGene Therapy and Genetic Counseling. Chapter 20
Gene Therapy and Genetic Counseling Chapter 20 What is Gene Therapy? Treating a disease by replacing, manipulating or supplementing a gene The act of changing an individual s DNA sequence to fix a non-functional
More informationFoto MCristof for SMC media. Italy 24February. www. eahad2012. .org. 5th EAHAD. European Association for Haemophilia and Allied Disorders
Foto MCristof for SMC media 22 ROME Italy 24February 2012 www. eahad2012.org 5th Annual Congress EAHAD European Association for Haemophilia and Allied Disorders Venue Ergife Palace Hotel and Congress Centre
More informationHealthcare Observer Jan 2013
d Healthcare Observer Jan 2013 The Hemophilia Market: Steep but Surmountable Barriers for New Entrants Since the 1990s, the hemophilia market has been dominated by recombinant proteins from Baxter, Bayer,
More informationAbnormal Basic Coagulation Testing Laboratory Testing Algorithms
Global Coagulation Testing Abnormal Basic Coagulation Testing Laboratory Testing Algorithms Jeffrey S. Jhang, M.D. No single global laboratory test Bleeding history is the strongest predictor of bleeding
More informationGenetic Engineering and Biotechnology
1 So, what is biotechnology?? The use of living organisms to carry out defined chemical processes for industrial or commercial application. The office of Technology Assessment of the U.S. Congress defines
More informationNational Patient Safety Goals Effective January 1, 2015
National Patient Safety Goals Goal 1 Nursing are enter ccreditation Program Improve the accuracy of patient and resident identification. NPSG.01.01.01 Use at least two patient or resident identifiers when
More informationGT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationHepatitis C Vaccines: Are we making progress?
Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify
More informationFACTOR XII DEFICIENCY AN INHERITED BLEEDING DISORDER AN INFORMATION BOOKLET
FACTOR XII DEFICIENCY AN INHERITED BLEEDING DISORDER AN INFORMATION BOOKLET Acknowledgements This information booklet on Factor XII Deficiency was prepared by: Nathalie Aubin Nurse Coordinator, Hemophilia
More informationSubcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.
Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D., FACS Learning Objectives After reading and reviewing this
More informationGenetic Testing in Research & Healthcare
We Innovate Healthcare Genetic Testing in Research & Healthcare We Innovate Healthcare Genetic Testing in Research and Healthcare Human genetic testing is a growing science. It is used to study genes
More informationRoche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
More informationTranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies
Overview Where We Use It And Why Andreas Antoniou, M.D., M.Sc. Department of Anesthesia and Perioperative Medicine University of Western Ontario November 14 th, 2009 Hemostasis Fibrinolysis Aprotinin and
More informationNONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
More informationAccelerating drug development to FTIH: Potential of new expression technologies
Accelerating drug development to FTIH: Potential of new expression technologies Lekan Daramola Associate Director Biopharmaceutical Development, Cell Culture & Fermentation Sciences CMC Strategy Forum
More informationLes traitements des hémophiles: histoire et perspectives
Les traitements des hémophiles: histoire et perspectives Pr Claude Négrier Centre national de référence de l hémophilie Hôpital Edouard Herriot Université Claude Bernard Lyon 1 claude.negrier@chu-lyon.fr
More informationStem cells and motor neurone disease
Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and how they may be used to create
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Hunter syndrome is a rare genetic disease which mainly affects males of all ethnicities. The incidence rate ranges from 0.6 to
More informationPlatelet Review July 2012. Thomas S. Kickler M.D. Johns Hopkins University School of Medicine
Platelet Review July 2012 Thomas S. Kickler M.D. Johns Hopkins University School of Medicine Hemostasis Hemostasis is the process that leads to the stopping of bleeding Hemostasis involves blood vessels,
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationYvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI
Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI Overview of Hematology, http://www.nu.edu.sa/userfiles/mhmorsy/h
More informationNHS FIFE WIDE POLICY - HAEMATOLOGY MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY
MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY The scope of this guideline is to simplify the management of patients on oral anticoagulation undergoing major and minor surgery.
More informationReference: NHS England B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
More informationCHAPTER 6: RECOMBINANT DNA TECHNOLOGY YEAR III PHARM.D DR. V. CHITRA
CHAPTER 6: RECOMBINANT DNA TECHNOLOGY YEAR III PHARM.D DR. V. CHITRA INTRODUCTION DNA : DNA is deoxyribose nucleic acid. It is made up of a base consisting of sugar, phosphate and one nitrogen base.the
More informationEuropean guidelines for the certification of Haemophilia Centres
European guidelines for the certification of Haemophilia Centres 07 June 2013 NOTICE These Standards are designed to provide minimum guidelines for European Haemophilia Centres. These Standards are not
More informationLiver Function Essay
Liver Function Essay Name: Quindoline Ntui Date: April 20, 2009 Professor: Dr. Danil Hammoudi Class: Anatomy and Physiology 2 Liver function The human body consist of many highly organize part working
More informationSTANDARD BLOOD PRODUCTS AND SERVICES
STANDARD BLOOD PRODUCTS AND SERVICES Policy NHP reimburses contracted providers for the medically necessary administration (transfusion) of blood and standard blood products. Prerequisites Authorization,
More informationDeveloping Innovative Therapeutics for People with Orphan Liver Disease
Developing Innovative Therapeutics for People with Orphan Liver Disease PIPELINE PROGRESS AND FIRST QUARTER 2015 EARNINGS UPDATE NASDAQ: OCRX Forward-Looking Statements Certain statements in this presentation
More information